Dr. Saar Gill of Penn receives $450K to advance gastroesophageal cancer treatment
The Penn physician-researcher has received more funding to advance his 'Trojan horse' for attacking gastroesophageal cancer.
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Dr. Rousseau to lead clinical development as Pheast advances PHST001, a novel anti-CD24 macrophage checkpoint inhibitor, into clinical trials. PALO ALTO, Calif., February 18, 2025 ...